Medicine Press release



Lecanemab Receives Priority Review Status in Japan
Jan 30, 2023 11:50 JST
Eisai Co., Ltd. and Biogen Inc. announced today that an application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI), an anti-amyloid-beta (Abeta) protofibril* antibody, in Japan has been designated for Priority Review by the Japanese Ministry of Health, Labour and Welfare (MHLW).
More info..


Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency
Jan 27, 2023 10:46 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab, an investigational anti-amyloid beta (Abeta) protofibril* antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) with confirmed amyloid pathology, for review following a standard timeline.
More info..


Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel
Jan 19, 2023 09:35 JST
Eisai Co., Ltd. announced today that fully-fledged operations and business activities have begun at Eisai Israel Ltd., a pharmaceutical sales subsidiary recently established in Tel Aviv in the State of Israel (Israel).
More info..


Eisai Listed as a Global 100 Most Sustainable Corporation for The Seventh Time Highest Ranked Global Pharmaceutical Company
Jan 19, 2023 08:07 JST
Eisai Co., Ltd. announced that it has been listed in the 2023 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc.
More info..


Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023
Jan 18, 2023 12:28 JST
Eisai Co., Ltd. announced today the presentation of research across various types of gastrointestinal cancers during the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI23), which is taking place in-person in San Francisco, California and virtually from January 19-21.
More info..


Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan
Jan 16, 2023 17:56 JST
Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a marketing authorization application for lecanemab.
More info..


Fujitsu and Sapporo Medical University launch joint project to realize data portability in the healthcare field
Jan 16, 2023 10:17 JST
Fujitsu and Sapporo Medical University today announced the launch of a joint project starting in April 2023 to realize data portability for patients' healthcare data including electronic health records (EHRs) and personal health records (PHRs).
More info..


Soligenix On Track to Deliver Important Front-Line Treatment to US Market in 2024
Jan 16, 2023 06:00 JST
PCG Digital -- Late-stage biopharmaceutical company, Soligenix, Inc. (Nasdaq: SNGX) is on track to deliver a safe and effective front-line treatment to a community of patients living with rare, chronic cancer.
More info..


Soligenix On Track to Deliver Important Front-Line Treatment to US Market in 2024
Jan 16, 2023 06:00 JST
PCG Digital -- Late-stage biopharmaceutical company, Soligenix, Inc. (Nasdaq: SNGX) is on track to deliver a safe and effective front-line treatment to a community of patients living with rare, chronic cancer.
More info..


Eisai Launches Renewed Sustainability Page
Jan 13, 2023 14:06 JST
Eisai Co., Ltd. announced that it has renewed the Sustainability page of its corporate website and it is now accessible to the public.
More info..